{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:44:29Z","timestamp":1648601069323},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Klin"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s00063-009-1152-1","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T04:57:47Z","timestamp":1253595467000},"page":"699-703","source":"Crossref","is-referenced-by-count":2,"title":["Wirkung der Enzymersatztherapie (ERT) auf die Nierenfunktion von Patienten mit Morbus Fabry"],"prefix":"10.1007","volume":"104","author":[{"given":"Thomas","family":"Thomaidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Relle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,23]]},"reference":[{"key":"1152_CR1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"R.O. Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163\u20137.","journal-title":"N Engl J Med"},{"key":"1152_CR2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"K.D. MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750\u201360.","journal-title":"J Med Genet"},{"key":"1152_CR3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"K.D. MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769\u201375.","journal-title":"J Med Genet"},{"key":"1152_CR4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"M.H. Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002;81:122\u201338.","journal-title":"Medicine (Baltimore)"},{"key":"1152_CR5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","volume":"19","author":"J. Kleinert","year":"2006","unstructured":"Kleinert J, Dehout F, Schwarting A, et al. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 2006;19:782\u20137.","journal-title":"Am J Hypertens"},{"key":"1152_CR6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A. Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236\u201342.","journal-title":"Eur J Clin Invest"},{"key":"1152_CR7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","volume":"118","author":"M. Ries","year":"2006","unstructured":"Ries M, Clarke JT, Whybra C, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006;118.924\u201332.","journal-title":"Pediatrics"},{"key":"1152_CR8","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"B.L. Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002;62:1933\u201346.","journal-title":"Kidney Int"},{"key":"1152_CR9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/01.ASN.0000016684.07368.75","volume":"13","author":"J. Alroy","year":"2002","unstructured":"Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002;13:134\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1152_CR10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","volume":"13","author":"M.C. Gubler","year":"1978","unstructured":"Gubler MC, Lenoir G, Grunfeld JP, et al. Early renal changes in hemizygous and heterozygous patients with Fabry\u2019s disease. Kidney Int 1978;13:223\u201335.","journal-title":"Kidney Int"},{"key":"1152_CR11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ki.2008.576","volume":"75","author":"T. Thomaidis","year":"2009","unstructured":"Thomaidis T, Relle M, Golbas M, et al. Down-regulation of \u03b1-galactosidase A up-regulates CD77: functional impact for Fabry nephropathy. Kidney Int 2009;75:399\u2013407.","journal-title":"Kidney Int"},{"key":"1152_CR12","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","volume":"94","author":"T. Ohshima","year":"1997","unstructured":"Ohshima T, Murray GJ, Swaim WD, et al. \u03b1-galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A 1997;94:2540\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1152_CR13","first-page":"A208","volume":"59","author":"A.M. Wang","year":"1996","unstructured":"Wang AM, Ioannou YA, Zeidner KM, et al. Generation of a mouse model with \u03b1-galactosidase deficiency. Am J Hum Genet 1996;59:Suppl:A208.","journal-title":"Am J Hum Genet"},{"key":"1152_CR14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","volume":"68","author":"Y.A. Ioannou","year":"2001","unstructured":"Ioannou YA, Zeidner KM, Gordon RE, et al. Fabry disease: preclinical studies demonstrate the effectiveness of \u03b1-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001;68:14\u201325.","journal-title":"Am J Hum Genet"},{"key":"1152_CR15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","volume":"97","author":"R. Schiffmann","year":"2000","unstructured":"Schiffmann R, Murray GJ, Treco D, et al. Infusion of \u03b1-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000;97:365\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1152_CR16","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R. Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743\u20139.","journal-title":"JAMA"},{"key":"1152_CR17","first-page":"222","volume":"69","author":"R. Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Moore DF, et al. Efficacy and safety of prolonged enzyme replacement therapy for Fabry disease. Am J Hum Genet 2001;69:Suppl:222.","journal-title":"Am J Hum Genet"},{"key":"1152_CR18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"C.M. Eng","year":"2001","unstructured":"Eng CM, Banikazemi M, Gordon RE, et al. A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001;68:711\u201322.","journal-title":"Am J Hum Genet"},{"key":"1152_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"C.M. Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, et al., International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human \u03b1-galactosidase A replacement in Fabry disease. N Engl J Med 2001;345:9\u201316.","journal-title":"N Engl J Med"},{"key":"1152_CR20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"W.R. Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, et al., International Fabry Disease Study Group. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65\u201374.","journal-title":"Am J Hum Genet"},{"key":"1152_CR21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2362.2004.01424.x","volume":"34","author":"M. Beck","year":"2004","unstructured":"Beck M, Ricci R, Widmer U, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004;34:338\u201344.","journal-title":"Eur J Clin Invest"},{"key":"1152_CR22","first-page":"77","volume":"66","author":"A. Schwarting","year":"2006","unstructured":"Schwarting A, Dehout F, Feriozzi S, et al. Enzyme replacement therapy in 201 patients with Fabry disease. Clin Nephrol 2006;66:77\u201384.","journal-title":"Clin Nephrol"},{"key":"1152_CR23","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","volume":"69","author":"F. Breunig","year":"2006","unstructured":"Breunig F, Weidemann F, Strotmann J, et al. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 2006;69:1216\u201321.","journal-title":"Kidney Int"},{"key":"1152_CR24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"D.P. Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase (beta) therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547\u201357.","journal-title":"J Am Soc Nephrol"},{"key":"1152_CR25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M. Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, et al., Fabry Disease Clinical Trial Study Group. Agalsidase-beta therapy in Fabry disease: a randomized trial. Ann Intern Med 2007;146:77\u201386.","journal-title":"Ann Intern Med"},{"key":"1152_CR26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1651-2227.2003.tb00214.x","volume":"92","author":"F. Dehout","year":"2003","unstructured":"Dehout F, Schwarting A, Beck M, et al. Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration in patients with Fabry disease: preliminary data. Acta Paediatr Suppl 2003;92:14\u20135.","journal-title":"Acta Paediatr Suppl"},{"key":"1152_CR27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","volume":"26","author":"F. B\u00e4hner","year":"2003","unstructured":"B\u00e4hner F, Kampmann C, Whybra C, et al. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 2003;26:617\u201327.","journal-title":"J Inherit Metab Dis"},{"key":"1152_CR28","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","volume":"65","author":"R. Mignani","year":"2004","unstructured":"Mignani R, Panichi V, Giudicissi A, et al. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney Int 2004;65:1381\u20135.","journal-title":"Kidney Int"},{"key":"1152_CR29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000168482","volume":"29","author":"S. Feriozzi","year":"2009","unstructured":"Feriozzi S, Schwarting A, Sunder-Plassmann G, et al. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 2009;29:353\u201361.","journal-title":"Am J Nephrol"},{"key":"1152_CR30","first-page":"595","volume":"163","author":"K. Mills","year":"2004","unstructured":"Mills K, Vellodi A, Morris P, et al. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease. Eur J Pediatr 2004;163:595\u2013603.","journal-title":"Eur J Pediatr"},{"key":"1152_CR31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","volume":"94","author":"E. Young","year":"2005","unstructured":"Young E, Mills K, Morris P, et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 2005;94:51\u20134.","journal-title":"Acta Paediatr Suppl"},{"key":"1152_CR32","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"J.M. Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Medizinische Klinik"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-009-1152-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00063-009-1152-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-009-1152-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T22:13:23Z","timestamp":1558563203000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00063-009-1152-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["1152"],"URL":"https:\/\/doi.org\/10.1007\/s00063-009-1152-1","relation":{},"ISSN":["0723-5003","1615-6722"],"issn-type":[{"value":"0723-5003","type":"print"},{"value":"1615-6722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}